Hsbc Holdings PLC Has $199.72 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Hsbc Holdings PLC lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 12.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,770,281 shares of the medical equipment provider’s stock after buying an additional 307,109 shares during the quarter. Hsbc Holdings PLC’s holdings in Hologic were worth $199,723,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in Hologic by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock worth $412,159,000 after purchasing an additional 144,838 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Hologic by 0.5% during the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after buying an additional 24,358 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Hologic by 3.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock valued at $322,272,000 after acquiring an additional 129,035 shares in the last quarter. Invesco Ltd. increased its position in shares of Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock valued at $293,434,000 after acquiring an additional 572,187 shares during the last quarter. Finally, Boston Partners raised its holdings in Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Finally, Raymond James reiterated an “outperform” rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Price Performance

NASDAQ:HOLX opened at $58.19 on Wednesday. Hologic, Inc. has a 52 week low of $55.89 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm’s 50-day simple moving average is $61.34 and its 200 day simple moving average is $70.45. The firm has a market cap of $13.06 billion, a price-to-earnings ratio of 18.36, a P/E/G ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.